Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Ranitidine HCl
Indication
Hypersecretory conditions, Prophylaxis of gastrointestinal haemorrhage from stress ulceration, Benign gastric and duodenal ulceration, Prophylaxis of acid aspiration during general anaesthesia.
Instruction
Administer via IM/slow IV.
Drug interaction
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.
Malaysia
